Intravenous immunoglobulins (IVIG)

DRUG3 trials

Sponsors

University of Giessen, University Hospital, Strasbourg, France, Janssen Research & Development, LLC

Conditions

Kidney TransplantationRenal Failure, ChronicRenal TransplantationThrombocytopenia, Neonatal Alloimmune

Early Phase 1

Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients

CompletedNCT00176059

University of GiessenRenal Failure, Chronic, Renal Transplantation

Start: 2001-10-31End: 2006-05-31Updated: 2007-05-10

Phase 3

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

RecruitingNCT06533098

Janssen Research & Development, LLCThrombocytopenia, Neonatal Alloimmune

Start: 2025-02-10End: 2029-12-05Target: 50Updated: 2026-03-13

Phase 4

Intravenous Immunoglobulins for Prevention of BKV Infection in Kidney Transplant Recipients According to BKV Genotype-specific Neutralizing Antibody Titers at the Day of Transplantation.

CompletedNCT04222023

University Hospital, Strasbourg, FranceKidney Transplantation

Start: 2022-08-21End: 2025-08-01Updated: 2025-08-06

Related Papers

Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA-3)

Blood2024-11-052 citations